scPharmaceuticals
SCPH
SCPH was delisted on the 6th of October, 2025.
0 hedge funds and large institutions have $0 invested in scPharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 109 closing their positions.
76.88% less ownership
Funds ownership: 76.88% → 0% (-77%)
100% less funds holding
Funds holding: 110 → 0 (-110)
100% less capital invested
Capital invested by funds: $232M → $0 (-$232M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 109
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$34.4M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$28.9M |
| 3 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$16.3M |
| 4 |
BlackRock
New York
|
-$13.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$12.3M |
SCPH Hedge Fund Activity: Q4 2025 in Review
0 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in scPharmaceuticals (SCPH) for Q4 2025, worth a combined $0 — down 100% from $232M a quarter earlier.
Sellers outnumbered buyers: 109 funds closed out of SCPH and 0 opened new positions — a net loss of 109 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was OrbiMed, exiting entirely with an estimated $34.4M sold.
- 0 institutional investors held scPharmaceuticals (SCPH) as of Q4 2025, down from 110 in Q3 2025.
- Funds reported $0 of scPharmaceuticals stock for Q4 2025, down 100% quarter-over-quarter.
- 0 funds opened new scPharmaceuticals positions in Q4 2025 and 109 closed out, a net change of -109 holders.
- The largest scPharmaceuticals seller in Q4 2025 was OrbiMed, an estimated $34.4M sold.
Based on aggregated 13F filings for Q4 2025.